Sign in

CIK 0002044950

Bambusa Therapeutics, Inc.

Sign in to watch
Ticker
BBTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
other
EIN
992083913
Phone
(617) 848-6188
Business address
22 BOSTON WHARF ROAD, FLOOR 7, BOSTON, MA
Open-market buys, last 90 days
$58,639,957
in 3 filings
Open-market sales, last 90 days
$0
in 0 filings

Net +$58,639,957. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. RA CAPITAL MANAGEMENT, L.P. +$46.6M Director 1 filing
  2. Jeggle Helmut Wolfgang +$6.0M Director 1 filing
  3. Salvia Investment GmbH +$6.0M 10% owner 1 filing
Date Insider Transaction Shares Price Value Owned after
2026-11-02 Xu Shanshan See remarks Conversion · Series A-1 Preferred Stock −15,789 0
2026-11-02 Jeggle Helmut Wolfgang Director Conversion +4,769,701 8,889,301
2026-11-02 Jeggle Helmut Wolfgang Director Purchase +375,000 $16.00 $6.0M 9,264,301
2026-11-02 Jeggle Helmut Wolfgang Director Conversion · Series Seed Plus Preferred Stock −3,135,066 0
2026-11-02 Jeggle Helmut Wolfgang Director Conversion · Series A-1 Preferred Stock −1,473,775 0
2026-11-02 Jeggle Helmut Wolfgang Director Conversion · Series A-2 Preferred Stock −160,860 0
2026-10-30 RA CAPITAL MANAGEMENT, L.P. Director Purchase +189,909 $14.23 $2.7M 189,909
2026-10-30 RA CAPITAL MANAGEMENT, L.P. Director Purchase +263,911 $14.92 $3.9M 453,820
2026-10-29 Xu Shanshan See remarks Grant or award · Stock Option (right to buy) +379,102 379,102
2026-10-29 Xu Shanshan See remarks Grant or award · Restricted Stock Units +758,204 758,204

Page 2 of 2 · 30 trades